Effect of HER2-Targeted Therapy on PDX and PDX-Derived Organoids Generated From HER2-Positive Salivary Duct Carcinoma

Using models of patient-derived xenograft (PDX) model, patient-derived organoids, and PDX-derived organoids for salivary duct carcinoma (SDC), researchers examined the therapeutic effect of human epidermal growth factor receptor 2 (HER2) blockade on HER2-positive SDC.